Results 161 to 170 of about 21,677 (267)

Outcomes and Usability of Formoterol-Budesonide Delivered Through Synchrobreathe^® in Patients With Chronic Obstructive Pulmonary Disease: The EMERGE Study. [PDF]

Drugs Real World Outcomes
Balamurugan S, Pophale H, Samariya U, Apte K, Singh S, Dhar R, Rajan S, Swarnakar R, Talwar D, Lopez M, Naik V, Sawant S, Chhowala S, Vaidya A, Gogtay J.   +14 more
europepmc   +1 more source

Cost-effectiveness modeling of mortality risk reduction comparing two fixed-dose combination triple therapies in moderate-to-very severe chronic obstructive pulmonary disease. [PDF]

J Comp Eff Res
Parsekar K, Pandey S, Tansey-Dwyer D, Marshall J, Rustignoli I, Pollack M, Singh B, Ouwens M.   +7 more
europepmc   +1 more source

A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β₂-Agonists Used for Asthma and COPD. [PDF]

Pharmacol Res Perspect
Proudman RGW, Baker JG.
europepmc   +1 more source

A Strategy to Reduce Out-of-User-Life Utilization and Waste of Expired Budesonide-Formoterol Pressurized Metered-Dose Inhalers in Mild Asthma. [PDF]

Ann Am Thorac Soc
Stein KR, Jost E, Barker AR, Simkovich SM, Goss CW, Agarwal M, Huffman MD, Sumino K, Pleasants R, Castro M, Reddel HK, Krings JG.   +11 more
europepmc   +1 more source

The Effects of Extrafine Beclometasone/Formoterol (BDP/F) on Lung Function, Dyspnea, Hyperinflation, and Airway Geometry in COPD Patients: Novel Insight Using Functional Respiratory Imaging [PDF]

, 2014
Jan De Backer, Wim Vos, Samir Vinchurkar, Cedric Van Holsbeke, Gianluigi Poli, Rita Claes, Rodrigo Salgado, Wilfried De Backer   +7 more
openalex   +1 more source

An anti-inflammatory reliever algorithm approach to asthma management in adults: an open-label, single-arm trial. [PDF]

EClinicalMedicine
Bruce P, Houghton C, Hatter L, Kearns C, Holliday M, Anderson AJ, Perry M, Boyd C, Eathorne A, Martindale J, Sparks J, Semprini A, Pavord I, Harrison T, Papi A, Horne R, Weatherall M, Beasley R.   +17 more
europepmc   +1 more source

Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment [PDF]

, 2016
Jill Davis, David M. Kern, Setareh A. Williams, Ozgur Tunceli, Bingcao Wu, Sally Hollis, Charlie Strange, Frank Trudo   +7 more
openalex   +1 more source

Correction: Real-world Comparative Effectiveness in Patients with Asthma Newly Initiating Fluticasone Furoate/Vilanterol or Budesonide/Formoterol: A United Kingdom General Practice Cohort Study. [PDF]

Pulm Ther
Woodcock A, Blakey J, Bourdin A, Canonica GW, Domingo C, Ford A, Hulme R, Tritton T, Palomares I, Sadhu S, Biswas A, Verma M.   +11 more
europepmc   +1 more source

Correction to: Real-World Comparative Effectiveness Study in Patients with Asthma Initiating Fluticasone Furoate/Vilanterol or Beclometasone Dipropionate/ Formoterol Fumarate in General Practice in England. [PDF]

Adv Ther
Woodcock A, Blakey J, Bourdin A, Canonica GW, Domingo C, Ford A, Hulme R, Tritton T, Palomares I, Sadhu S, Biswas A, Verma M.   +11 more
europepmc   +1 more source

Effect of triple inhaled therapy on MACE and cardiovascular events in COPD: a systematic review and meta-analysis. [PDF]

Front Cardiovasc Med
Calderón-Montero A, de Miguel Díez J, Barrios V, Calderón-Ferrer C, Joshi M.   +4 more
europepmc   +1 more source